Evidence map›Paper›PMID 25621800›Full record

ArticleBone marrow transplantation2015

Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search.

A A Hamidieh, M Ostadali Dehaghi, P Paragomi, S Navaei, A Jalali, G Ghazizadeh Eslami, M Behfar, A Ghavamzadeh

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Outcomes Following Allogeneic Stem Cell Transplantation Using Non-sibling Family Donors.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

A A HamidiehHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of MedicalSciences, Tehran, Iran.
M Ostadali DehaghiHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of MedicalSciences, Tehran, Iran.
P ParagomiHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of MedicalSciences, Tehran, Iran.
S NavaeiHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of MedicalSciences, Tehran, Iran.
A JalaliHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of MedicalSciences, Tehran, Iran.ORCID 0000000332258498
G Ghazizadeh EslamiHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of MedicalSciences, Tehran, Iran.
M BehfarHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of MedicalSciences, Tehran, Iran.
A GhavamzadehHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of MedicalSciences, Tehran, Iran.
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The best donors for hematopoietic SCT (HSCT) are fully-matched siblings. In patients without fully-matched siblings, HLA registries or cord blood banks are alternative strategies with some restrictions. Owing to the high rate of consanguineous marriage in our country, between 2006 and 2013, extended family searches were undertaken in Hematology-Oncology Research Center and Stem Cell Transplantation (HORCSCT), Tehran, Iran, in 523 HSCT candidates with parental consanguinity and no available HLA identical sibling. Fully-matched other-relative donors were found for 109 cases. We retrospectively studied the HSCT outcome in these patients. Median time to neutrophil engraftment was 13 days (range: 9-31days). In 83 patients, full chimerism and in 17 patients, mixed chimerism was achieved. Acute GvHD (aGvHD) grade II-IV appeared in 36 patients (33%). The frequency of aGvHD development in various familial subgroups was NS. Five patients expired before day+100. In the surviving 104 cases, chronic GvHD developed in 20 patients (19.2%). The distantly related subgroup had significantly a higher rate of cGvHD (P=0.04). The 2-year OS and disease-free survival (DFS) were 76.7±4.5% and 71.7±4.7%, respectively. No significant difference in OS (P=0.30) and DFS (P=0.80) was unraveled between various familial relationships. Our considerable rate of fully-matched non-sibling family members and the favorable outcome support the rationale for extended family search in regions where consanguineous marriage is widely practiced.

Indexed as

Hematopoietic Stem Cell TransplantationHLA AntigensUnrelated DonorsAcute DiseaseAdolescentAdultAllograftsChildChild, PreschoolDisease-Free SurvivalDonor SelectionFamilyFemaleFollow-Up StudiesGraft vs Host DiseaseHematologic DiseasesHLA Antigens

Identifiers

PMID25621800
OpenAlexW2056585884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.